Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
9 High-Yield Dividend Aristocrat Bargain Buys
07:00am, Saturday, 29'th Jun 2024
The market remains near record highs with the best-ever presidential election year return and 13th-best S&P return through the first half of the year. Free cash flow yield is the best valuation metric
Here's Why Novartis (NVS) is a Strong Value Stock
10:46am, Monday, 24'th Jun 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
11 Sleep Well At Night Blue-Chip Bargains For Today's Overvalued Market
07:00am, Saturday, 22'nd Jun 2024
Stocks have been on fire since October lows, with many investors worried about bubbles and looming corrections. Even with the market at an all-time high, there are always extraordinary blue-chip barga
Here's Why Novartis (NVS) is a Strong Momentum Stock
10:55am, Thursday, 20'th Jun 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG's Minority Shareholders
02:20am, Thursday, 20'th Jun 2024
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to me
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
03:27pm, Monday, 17'th Jun 2024
Biotech stocks operate under a core ethos. While there's been much talk about financially viable sectors – from tech to cryptocurrencies to even precious metals – when you think about it, nothing
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
11:39am, Thursday, 13'th Jun 2024
Pending regulatory submission, Fabhalta (iptacopan) could become the first approved therapy for C3G, addressing a significant unmet need in nephrology, according to Spherix Global Insights. Pending re
Why Novartis (NVS) is a Top Value Stock for the Long-Term
10:46am, Thursday, 06'th Jun 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Novartis and others face Italy antitrust probe over eye drug
03:16am, Thursday, 06'th Jun 2024
Italy's antitrust regulator said on Thursday it had launched a probe into several pharmaceutical companies, including Novartis , for having potentially restricted competition in the sale of a drug for
The 3 Most Undervalued Healthcare Stocks to Buy in June 2024
02:18pm, Tuesday, 04'th Jun 2024
When it comes to seeking discounts, investors may do well with undervalued healthcare stocks. Primarily, that's because with this sector, you're dealing with a permanently relevant narrative.
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
10:56am, Tuesday, 04'th Jun 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novartis AG (NVS) Investor Event at ASCO Conference Call (Transcript)
05:24pm, Monday, 03'rd Jun 2024
Novartis AG (NYSE:NVS ) Investor Event at ASCO Conference Call June 2, 2024 7:00 PM ET Company Participants Parag Mahanti - Investor Relations Shreeram Aradhye - President of Global Drug Development a
Novartis (NVS) Reports Positive Long-Term Data on CSU Drug
02:06pm, Friday, 31'st May 2024
Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
Novartis CEO: Our leukemia drug Scemblix is a potential $3 billion plus medicine
12:32pm, Friday, 31'st May 2024
Vas Narasimhan, Novartis CEO, joins 'Squawk on the Street' to discuss the company's positive Leukemia drug results, the review timeline for Scemblix, and insights into Novartis' breast cancer drug.
Novartis leukemia drug more effective than older treatments in trial
08:12am, Friday, 31'st May 2024
Swiss drugmaker Novartis said patients with a type of leukemia who took its Scemblix had a significantly better response and a lower dropout rate than those who received current standard-of-care drugs
